**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 63282

**Manuscript Type:** CASE REPORT

**Aspirin-induced long-term tumor remission in hepatocellular carcinoma with adenomatous polyposis coli stop-gain mutation: A case report**

Lin Q *et al*. Aspirin in HCC with APC mutation

Qu Lin, Ming-Jun Bai, Hao-Fan Wang, Xiang-Yuan Wu, Ming-Sheng Huang, Xing Li

**Qu Lin, Xiang-Yuan Wu, Xing Li,** Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China

**Ming-Jun Bai, Hao-Fan Wang, Ming-Sheng Huang,** Department of Intervention and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China

**Author contributions:** Lin Q and Huang MS recruited the patient and made clinical decisions; Bai MJ and Wang HF carried out the follow up; Li X, Wang HF and Bai MJ performed the image analysis; Li X performed the molecular analysis; Lin Q, Huang MS, Wu XY and Li X carried out the molecular pathway analysis; Li X wrote the manuscript; Huang MS is the co-corresponding author.

**Supported by** Guangzhou Science and Technology Project, No. 201904010461; and Major Talents Project of Guangdong Province, No. 2019TQ05Y266.

**Corresponding author: Xing Li, MD, Professor,** Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. lixing9@mail.sysu.edu.cn

**Received:** February 1, 2021

**Revised:** April 6, 2021

**Accepted:** May 18, 2021

**Published online:** August 26, 2021

**Abstract**

BACKGROUND

Targeted therapy based on pathway analysis of hepatitis B-related hepatocellular carcinoma (HCC) may be a promising remedy.

CASE SUMMARY

The present case involved an advanced hepatocellular carcinoma (HCC) patient who did not receive local regional therapy and was intolerant to sorafenib. Total RNA extracted from the patient’s tumor tissue was used to obtain the gene mutation profile. The c.3676A>T and c.4402A>T stop-gain mutations in adenomatous polyposis coli (APC) were the most prevalent (42.2% and 35.1%, respectively). MutationMapper analysis indicated that the functional domain of APC was lost in the two APC mutant genes. APC is a major suppressor of the Wnt signaling pathway. Thus, the Wnt pathway was exclusively activated due to APC dysfunction, as other elements of this pathway were not found to be mutated. Aspirin has been reported to suppress the Wnt pathway by inducing β-catenin phosphorylation through the activation of glycogen synthase kinase 3 beta *via* cyclooxygenase-2 pathway inhibition. Therefore, aspirin was administered to the patient, which achieved four years of disease control.

CONCLUSION

Exclusive mutations of APC of all the Wnt pathway elements could be a therapeutic target in HCC, with aspirin as an effective treatment option.

**Key Words:** Hepatocellular carcinoma; Mutation; Wnt pathway; Aspirin; Adenomatous polyposis coli; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lin Q, Bai MJ, Wang HF, Wu XY, Huang MS, Li X. Aspirin-induced long-term tumor remission in hepatocellular carcinoma with adenomatous polyposis coli stop-gain mutation: A case report. *World J Clin Cases* 2021; 9(24): 7189-7195

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i24/7189.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i24.7189

**Core Tip:** Hepatocellular carcinoma (HCC) is a highly heterogeneous disease. Due to the differences in etiology and ethnicities, the driving genes in HCC are likely to be different globally. Adenomatous polyposis coli (APC) mutations are critical in a fraction of HCC patients, as APC mutations might trigger HCC by activating the Wnt pathway. The effects of this mutation could be consistently suppressed by aspirin. Thus, APC mutation-triggered HCC might be a new subgroup of chronic hepatitis B virus infection-related HCC. Wnt pathway inhibition could be an effective remedy for this subgroup of patients.

**INTRODUCTION**

Some small molecular agents with multiple targets, including sorafenib, lenvatinib, and regorafenib, are reported to be effective against hepatocellular carcinoma (HCC)[1]. However, the efficacy of these agents is unpredictable. As the average overall survival of patients with advanced HCC is only approximately three months[2], primary resistance to first-line treatment may prevent the possibility of second-line remedies. Thus, precise therapy is needed for the treatment of advanced HCC.

In this era of precise therapy, treatments can be administered with maximum efficacy if the target is clearly identified. For the multi-targeted agents used for HCC, unsatisfactory safety profiles and limited improvement in overall survival have hindered their use in the treatment of advanced HCC. RNA sequencing can be used to identify the causative gene mutations in tumor tissues to provide more accurate targets for the treatment of HCC.

In this case of advanced HCC, we screened for mutations in an HCC patient using the Illumina Hiseq2000 platform and identified mutated adenomatous polyposis coli (APC) as the major driver gene. Aspirin was chosen as the targeted agent to treat this patient, which achieved disease control for at least four years.

**CASE PRESENTATION**

***Chief complaints***

Recurrent HCC with APC stop-gain mutation.

***History of present illness***

A Chinese male patient with chronic hepatitis B infection was admitted to the Cancer Center of Sun Yat-sen University for the treatment of HCC identified in the S6 segment of the liver by contrast computed tomography (CT) scan in June 2012. Radical resection was performed. Tumor recurrence was observed in March 2014. Transcatheter arterial chemoembolization (TACE) was performed followed by radiofrequency ablation with radical intent. However, the tumor recurred at the juncture of the S2 and S3 sections in September 2014. The tumor was resected. The tumor recurred in February 2015. A series of TACE procedures were performed as palliative local regional therapy from February 2015 to October 2016 at the Third Affiliated Hospital of Sun Yat-sen University. Sorafenib was administered after the first cycle of palliative TACE, but the treatment was suspended one month later due to grade III diarrhea. In that period, tumor progression was noted three times, which made local regional therapy an inappropriate choice for disease control. Alteration of alpha-fetoprotein indicated the efficacy of each therapy (Figure 1A).

***History of past illness***

Untreated chronic hepatitis B.

***Personal and family history***

None.

***Physical examination***

Normal.

***Laboratory examinations***

RNA sequence-based precise therapy was also considered. RNA sequencing was conducted on recurrent tumor tissue from a needle core biopsy in April 2016 to identify the gene mutation(s). Sequencing revealed that APC mutations are the major driver mutations. Stop-gain c.3676A>T and c.4402A>T APC mutations were the most prevalent (42.2% and 35.1%, respectively). ABL1 missense mutations, *TP53* stop-gain, and *TNFAIP3* missense mutations were less frequent (Table 1).

The amino acid sequences of APC mutations indicated a strongly truncated APC protein (Supplementary data). MutationMapper analysis indicated that the functional domain of APC was lost in both mutants in HCC tissue (Figure 1B).

***Imaging examinations***

Recurrent HCC was revealed by CT.

***Gene mutations screen***

Gene mutations were screened from HCC tissue samples from four patients and circulating tumor DNA samples from 41 HCC patients at The Third Affiliated Hospital of Sun Yat-sen University between February 2016 to January 2018 using the Illumina Hiseq2000 platform. Their gene mutation profiles were compared with those of the global HCC population from the Catalog of Somatic Mutations in Cancer (COSMIC) database. For patients with APC mutations, the amino acid sequences of APC mutations were evaluated using the Mutation Taster (http:// www.mutationtaster.org/) program. Using amino acid sequences generated by Mutation Taster, MutationMapper[3] was used to analyze the functional defects of the APC mutants.

***HCC gene mutation profile of hepatitis B-related HCC***

The gene mutation profile of Chinese patients with HCC was different to that of the global HCC population from the COSMIC database. According to our RNA sequence analysis of tumor tissues (*n* = 4) and circulating tumor DNA samples (*n* = 41) from hepatitis B-related HCC patients, the most prevalent mutated genes were *TP53, APOB, KMT2D, LRP1B, EGFR, ATM, CHD7, CTNNB1, ARID1A, TSC2, FAT4, HNF1A, PTPRB,* and *APC* (Figure 2A). This profile differed from the COSMIC global data (Figure 2B). Among the top 20 most frequent mutation genes, *APOB, EGFR, ATM, CHD7, PTPRB, APC,* and *GNAS* mutations were much more frequent among Chinese patients with HCC. Thus, these mutations may be potential targets for precise therapy.

APC is a major suppressive regulator of the Wnt pathway[4]. In this pathway, APC and glycogen synthase kinase 3 beta (GSK3β) combined with Wnt pathway key regulator β-catenin induces β-catenin phosphorylation and degradation to avoid Wnt pathway over-activation. The Wnt pathway can be activated by multiple causes in HCC, including mutations in Axin1, Axin2, and β-catenin[5]. However, mutations in APC and GSK3β are rare[6]. In the present study, APC was the only mutated gene in the Wnt pathway, which was presumed to be the exclusive cause of Wnt pathway over-activation. Due to the potentially normal function of other elements of the Wnt pathway, decreased β-catenin phosphorylation was the only trigger for this pathway. Thus, acceleration of β-catenin phosphorylation might abrogate the Wnt pathway, implicating GSK3β as a potential target.

**FINAL DIAGNOSIS**

Recurrent HCC with APC stop-gain mutation.

**TREATMENT**

Aspirin is reported to be effective in inducing β-catenin phosphorylation by activating GSK3β due to inhibition of the cyclooxygenase 2 (COX2) pathway[7]. As the COX2 pathway was assumed to act normally, high-dose aspirin (0.3 g/day) was chosen as a remedy from April 2016.

**OUTCOME AND FOLLOW-UP**

This strategy achieved disease control for almost 5 years until February 2021, as confirmed by magnetic resonance imaging and monitoring of alpha fetoprotein. The treatment was well tolerated (Figure 1A and C).

**DISCUSSION**

HCC is a highly heterogeneous disease[8]. The etiology of HCC in Chinese individuals is mainly chronic hepatitis B virus infection, which is quite different to that in European patients, for whom HCC is caused mainly by alcohol and chronic hepatitis C virus infection[2]. Due to the differences in etiology and ethnicities, the driving genes in HCC must be different globally. According to our data, APC mutations were among the top 20 most frequent mutations. However, in the COSMIC database, APC mutations are very rare, and few APC mutations related to HCC have been reported[6]. In the present case, we found an APC mutation that triggered HCC. The effects of this mutation could be consistently suppressed by aspirin. Thus, APC mutation-triggered HCC might be a new subgroup of chronic hepatitis B virus infection-related HCC. Wnt pathway inhibition could be an effective remedy for this subgroup of patients.

The Wnt pathway has been reported to be very important in the development of malignancies[9]. Approximately 20% of HCC patients reportedly display Wnt pathway activation[5]. The causes of Wnt pathway over-activation are complex. The importance of Wnt over-activation in the development of HCC could differ from one patient to another, which might not be evident in a large cohort study. Thus, the Wnt inhibitor failed to show reliable efficacy among non-selected HCC patients. In the present case, an APC mutation triggered HCC and the Wnt pathway was exclusively activated by APC dysfunction, as other elements of the Wnt pathway were not mutated. Knowledge of the Wnt pathway and its association with the COX2 pathway has led to the use of COX2 inhibitors[7], including the COX inhibitor aspirin and the selective COX2 inhibitors celecoxib and meloxicam, which are clinically available. In the present case, we chose aspirin and achieved long-term disease control.

The diagnosis of HCC does not rely on a pathologic test[2], which decreases the availability of RNA sequences in tumor tissues. The lack of tumor tissue gene mutation information, especially for advanced and recurrent diseases, has limited the extensive application of precisely designed targeted therapy based on dominant driver genes. Thus, needle biopsy might be of potential benefit for advanced and recurrent HCC. The present case demonstrates that RNA sequencing of HCC tissues might be a valuable approach and that the current HCC diagnostic procedure without histological tests might be insufficient for precise targeted therapy.

**CONCLUSION**

In the present case, the success of aspirin treatment was based on the dominant genetically driven Wnt pathway and exclusive mutation of APC among all the Wnt pathway elements, as discovered by RNA sequencing.

**REFERENCES**

1 **Heimbach JK**, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018; **67**: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29086]

2 **Li X**, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, Wan XB, Wen JY, Wei L, Chen J, Wu XY. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. *Asia Pac J Clin Oncol* 2013; **9**: 86-92 [PMID: 23279888 DOI: 10.1111/ajco.12050]

3 **Vohra S**, Biggin PC. Mutationmapper: a tool to aid the mapping of protein mutation data. *PLoS One* 2013; **8**: e71711 [PMID: 23951226 DOI: 10.1371/journal.pone.0071711]

4 **Giles RH**, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim Biophys Acta* 2003; **1653**: 1-24 [PMID: 12781368 DOI: 10.1016/s0304-419x(03)00005-2]

5 **Takigawa Y**, Brown AM. Wnt signaling in liver cancer. *Curr Drug Targets* 2008; **9**: 1013-1024 [PMID: 18991612 DOI: 10.2174/138945008786786127]

6 **Chen TC**, Hsieh LL, Ng KF, Jeng LB, Chen MF. Absence of APC gene mutation in the mutation cluster region in hepatocellular carcinoma. *Cancer Lett* 1998; **134**: 23-28 [PMID: 10381126 DOI: 10.1016/s0304-3835(98)00238-9]

7 **Gala MK**, Chan AT. Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. *Clin Cancer Res* 2015; **21**: 1543-1548 [PMID: 25501125 DOI: 10.1158/1078-0432.CCR-14-0877]

8 **Hammoud GM**, Ibdah JA. Are we getting closer to understanding intratumor heterogeneity in hepatocellular carcinoma? *Hepatobiliary Surg Nutr* 2016; **5**: 188-190 [PMID: 27115014 DOI: 10.3978/j.issn.2304-3881.2016.01.06]

9 **Barker N**, Clevers H. Mining the Wnt pathway for cancer therapeutics. *Nat Rev Drug Discov* 2006; **5**: 997-1014 [PMID: 17139285 DOI: 10.1038/nrd2154]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 1, 2021

**First decision:** March 7, 2021

**Article in press:** May 18, 2021

**Specialty type:** Medicine, Research and Experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Di Pasqua LG, lee Y **S-Editor:** Wang JL **L-Editor:** Webster JR **P-Editor:** Liu JH

**Figure Legends**





**Figure 1 Patient information.** A: Changes in alpha fetoprotein during treatment. B: Mutation map of adenomatous polyposis coli domains; C: Changes in tumor masses by magnetic resonance imaging before and after aspirin treatment. APC: Adenomatous polyposis coli; TACE: Transcatheter arterial chemoembolization.



**Figure 2 Gene mutation profiles.** A: Patients with hepatitis B-related hepatocellular carcinoma (HCC, *n* = 41); B: Global HCC population from the Catalogue of Somatic Mutations in Cancer database. COSMIC: Catalogue of Somatic Mutations in Cancer database.

**Table 1 Gene mutation analysis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Mutation type** | **Mutation ratio (%)** | **Nucleotide change** | **Amino acid change** | **Chromosome** | **Genbank transcript ID** |
| *ABL 1* | Missense | 30.2 | c.1363G>C | p.Asp455His | 9 | NM\_005157 |
| *APC* | Stop-gain | 42.2 | c.3676A>T | p.Lys1226X | 5 | NM\_000038 |
| *APC* | Stop-gain | 35.1 | c.4402A>T | p.Lys1468X | 5 | NM\_000038 |
| *TP53* | Stop-gain | 27.7 | c.193A>T | p.Arg65X | 17 | NM\_000546 |
| *TNFAIP3* | Missense | 5.5 | c.1787G>A | p.Arg596Gln | 6 | NM\_001270507 |
| *Gene* | Mutation type | Folds | Starting position | Ending position | Chromosome | Genbank transcript ID |
| *MDM4* | Amplification | 1.9 | 204485510 | 204527248 | 1 | N/A |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**